Felix Dobbs

Felix Dobbs has extensive experience in the field of biosciences. Starting in 2015, they worked as a Masters Research Student at Cardiff University, where they focused on developing tools to assess the delivery of biologics. During this time, they developed a single genetically-encoded reporter system.

In 2016, Felix became a BBSRC/AstraZeneca CASE PhD Student at Cardiff University. Their research project involved developing genomic tools for determining the off-target effects of CRISPR-Cas9 genome editing. The outcome of their work led to the formation of Broken String Biosciences Ltd, where they currently hold the position of Co-Founder & CEO.

Felix also briefly worked as a BBSRC/AstraZeneca CASE PhD Student at AstraZeneca in 2018.

Overall, Felix Dobbs has a strong background in biosciences, with a focus on developing tools and technologies for safe and effective genome editing and drug delivery.

Felix Dobbs pursued their education in the field of genetics. Felix completed their Bachelor's Degree at Cardiff University / Prifysgol Caerdydd from 2012 to 2015. Afterward, they obtained a Master's Degree in MRes Biosciences from the same university during the academic year 2015-2016. Felix continued their academic journey at Cardiff University / Prifysgol Caerdydd, working towards a Doctor of Philosophy (Ph.D.) in CRISPR/Cas9 Genome editing. Felix successfully completed their Ph.D. program in 2021, demonstrating their dedication and expertise in the field.